Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
ASH Highlights
Meeting Highlights
ASH Highlights
Depth of Response of Isatuximab + Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Interim Analysis
Read More
Meeting Highlights
ASH Highlights
Teclistamab, a BCMA x CD3 Bispecific Antibody, in Patients with RRMM: Phase 1 Study Updates
Read More
Meeting Highlights
ASH Highlights
Talquetamab, a G Protein–Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, for RRMM
Read More
Meeting Highlights
ASH Highlights
Novel Therapeutic Strategies with P-BCMA-101 CAR T-Cells in Patients with RRMM: Phase 1/2 Study Results
Read More
Meeting Highlights
ASH Highlights
REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with RRMM
Read More
Meeting Highlights
ASH Highlights
ANCHOR: Melflufen + Dexamethasone and Daratumumab or Bortezomib in RRMM Patients Refractory to an IMiD and/or Proteasome Inhibitor
Read More
Meeting Highlights
ASH Highlights
Systematic Review and Network Meta-Analysis of the Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-Refractory Multiple Myeloma
Read More
Meeting Highlights
ASH Highlights
APOLLO: Daratumumab + Pomalidomide and Dexamethasone versus Pomalidomide and Dexamethasone Alone in Patients with RRMM
Read More
Meeting Highlights
ASH Highlights
BFCR4350A, a FcRH5 x CD3 T-Cell–Engaging Bispecific Antibody, in Patients with RRMM: Preliminary Clinical Activity and Safety
Read More
Meeting Highlights
ASH Highlights
Cobimetinib as Monotherapy and in Combination with Venetoclax with or without Atezolizumab in Patients with RRMM
Read More
1
2
3
4
5
6
Page 3 of 7
Results 21 - 30 of 70